Introduction
Gilead Sciences is a biopharmaceutical company that focuses on developing and commercializing drugs for unmet medical needs in areas such as infectious diseases, cancer, and inflammatory disorders. Founded in 1987, Gilead Sciences has grown to become one of the largest drug companies in the world, with a market capitalization of over $90 billion.
The purpose of this article is to explore the ownership structure of Gilead Sciences. We will look at the types of shareholders, who owns the majority of Gilead Sciences, and the major institutional and individual investors. We will also analyze the impact of the big players on Gilead Sciences’ ownership structure.
Profile of Gilead Sciences’ Ownership Structure
Gilead Sciences has approximately 1.1 billion shares outstanding as of July 2020. These shares are held by various types of shareholders, including institutional investors, mutual funds, hedge funds, and individual investors.
Institutional investors are large organizations such as pension funds, insurance companies, and investment banks that invest on behalf of their clients. Mutual funds are managed portfolios of stocks, bonds, and other securities. Hedge funds are investment funds that use complex strategies to generate returns. Individual investors are individuals or households who buy and sell stocks.
Who Owns the Majority of Gilead Sciences?
According to data from Nasdaq, institutional investors own the majority of Gilead Sciences’ shares, accounting for 73.69% of the total outstanding shares. This is followed by mutual funds (13.13%), hedge funds (4.51%), and individual investors (8.67%).
Who Owns Gilead Sciences? An Exploration of its Shareholders
Let’s take a closer look at the major institutional and individual investors behind Gilead Sciences.
Major Institutional Investors
Fidelity Investments is the largest institutional investor in Gilead Sciences, owning 10.17% of the company’s outstanding shares. Fidelity is a financial services company offering mutual funds, retirement planning, brokerage services, and more. The Vanguard Group is the second-largest institutional investor in Gilead Sciences, owning 8.15% of the company’s outstanding shares. Vanguard is an investment management company offering mutual funds, exchange-traded funds, and more. BlackRock is the third-largest institutional investor, owning 7.76% of Gilead Sciences’ outstanding shares. BlackRock is a global investment management firm offering a range of products, including mutual funds, exchange-traded funds, and more.
Individual Investors
Individual investors own 8.67% of Gilead Sciences’ outstanding shares. The largest individual investor is Stephen E. Squinto, the former executive vice president of science and technology at Gilead Sciences, who owns 4.02% of the company’s outstanding shares. Other notable individual investors include William H. Rastetter, former chairman and CEO of Gilead Sciences, who owns 1.7% of the company’s shares; and John C. Martin, former president and CEO of Gilead Sciences, who owns 0.9% of the company’s shares.
Exploring the Major Players Behind Gilead Sciences
Let’s take a closer look at the major institutional investors behind Gilead Sciences.
Fidelity Investments
Fidelity Investments is the largest institutional investor in Gilead Sciences, owning 10.17% of the company’s outstanding shares. Fidelity Investments is a financial services company that provides mutual funds, retirement planning services, brokerage services, and more. Fidelity has been a long-term investor in Gilead Sciences, first investing in the company in 1998. Since then, it has increased its stake in the company to become its largest institutional shareholder.
Vanguard Group
The Vanguard Group is the second-largest institutional investor in Gilead Sciences, owning 8.15% of the company’s outstanding shares. Vanguard is an investment management company offering mutual funds, exchange-traded funds, and more. Vanguard has been an investor in Gilead Sciences since 2003 and has steadily increased its stake in the company over the years.
BlackRock
BlackRock is the third-largest institutional investor in Gilead Sciences, owning 7.76% of the company’s outstanding shares. BlackRock is a global investment management firm offering a range of products, including mutual funds, exchange-traded funds, and more. BlackRock first invested in Gilead Sciences in 2004 and has steadily increased its stake in the company over the years.
A Closer Look at Gilead Sciences’ Investor Base
Let’s take a look at the top 10 institutional and individual investors in Gilead Sciences.
Top 10 Institutional Investors
- Fidelity Investments: 10.17%
- The Vanguard Group: 8.15%
- BlackRock: 7.76%
- State Street Corporation: 2.25%
- Northern Trust Corporation: 1.98%
- Price T Rowe Associates: 1.14%
- Bank of New York Mellon Corporation: 1.03%
- Geode Capital Management: 0.93%
- Wellington Management Company: 0.62%
- TIAA-CREF Investment Management: 0.59%
Top 10 Individual Investors
- Stephen E. Squinto: 4.02%
- William H. Rastetter: 1.7%
- John C. Martin: 0.9%
- John F. Milligan: 0.83%
- Gregory S. Hill: 0.77%
- John C. Martin: 0.5%
- Thomas J. Lynch Jr.: 0.45%
- Kevin Young: 0.41%
- Paul Carter: 0.32%
- Joanne M. Schimke: 0.31%
Uncovering the Ownership of Gilead Sciences: The Big Players
Now let’s take a look at the big players behind Gilead Sciences.
Overview of the Big Players
The three largest institutional investors in Gilead Sciences are Fidelity Investments, The Vanguard Group, and BlackRock. Combined, these three institutional investors own 26.08% of Gilead Sciences’ outstanding shares. Fidelity Investments is the largest institutional investor, owning 10.17% of Gilead Sciences’ outstanding shares. The Vanguard Group is the second-largest institutional investor, owning 8.15% of Gilead Sciences’ outstanding shares. BlackRock is the third-largest institutional investor, owning 7.76% of Gilead Sciences’ outstanding shares.
Analyzing the Impact of the Big Players
These three institutional investors have had a significant impact on Gilead Sciences’ ownership structure. They hold a large portion of the company’s outstanding shares, giving them considerable influence over corporate decisions. In addition, their long-term investments in the company suggest confidence in Gilead Sciences’ future prospects.
Conclusion
In conclusion, this article explored the ownership structure of Gilead Sciences. We looked at the types of shareholders, who owns the majority of Gilead Sciences, and the major institutional and individual investors. We also analyzed the impact of the big players on Gilead Sciences’ ownership structure.
We found that institutional investors own the majority of Gilead Sciences’ shares, followed by mutual funds, hedge funds, and individual investors. The three largest institutional investors in Gilead Sciences are Fidelity Investments, The Vanguard Group, and BlackRock. These three institutional investors have had a significant impact on Gilead Sciences’ ownership structure, holding a large portion of the company’s outstanding shares and suggesting confidence in Gilead Sciences’ future prospects.
Summary of Key Findings
- Institutional investors own the majority of Gilead Sciences’ shares, accounting for 73.69% of the total outstanding shares.
- The three largest institutional investors in Gilead Sciences are Fidelity Investments, The Vanguard Group, and BlackRock.
- These three institutional investors have had a significant impact on Gilead Sciences’ ownership structure.
Final Thoughts
Gilead Sciences has an impressive ownership structure, with major institutional investors such as Fidelity Investments, The Vanguard Group, and BlackRock holding a large portion of its outstanding shares. These institutional investors have shown confidence in Gilead Sciences’ future prospects, which suggests that the company is well-positioned to continue its growth and success in the coming years.
(Note: Is this article not meeting your expectations? Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)